Kymera (KYMR) director receives 6,068 options at $99.87 strike price

Rhea-AI Filing Summary

Kymera Therapeutics director John Maraganore received a grant of stock options covering 6,068 shares of common stock. The options have an exercise price of $99.87 per share and expire on June 23, 2036. All 6,068 options were reported as directly owned after the transaction. According to the footnote, these options vest in full on the earlier of June 24, 2027 or the date of Kymera’s next annual stockholder meeting.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MARAGANORE JOHN

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	6,068	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 6,068 shares (Direct)

Footnotes (1)

1. F1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

Key Figures

Options granted: 6,068 options Exercise price: $99.87 per share Underlying shares: 6,068 shares +3 more

6 metrics

Options granted 6,068 options Stock Option (Right to Buy) grant to director

Exercise price $99.87 per share Conversion or exercise price of options

Underlying shares 6,068 shares Common stock underlying the options

Post-transaction options held 6,068 options Total derivative securities following transaction

Expiration date June 23, 2036 Option expiration

Vesting date trigger June 24, 2027 Earlier of this date or next annual meeting

Key Terms

Stock Option (Right to Buy), Grant, award, or other acquisition, vest in full, annual meeting of the Issuer's stockholders

4 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

vest in full financial

"The shares underlying this stock option shall vest in full upon the earlier"

annual meeting of the Issuer's stockholders financial

"earlier to occur of June 24, 2027 and the date of the next annual meeting"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/25/2026 - 06:00 PM Accepted by SEC EDGAR 06/25/2026 - 06:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Kymera Therapeutics (KYMR) report for John Maraganore?

Kymera disclosed that director John Maraganore received a grant of 6,068 stock options. These options give him the right to buy Kymera common shares at a fixed exercise price, reflecting a non-cash award rather than an open-market purchase or sale.

How many Kymera (KYMR) shares are covered by John Maraganore’s new options?

The stock option grant covers 6,068 shares of Kymera common stock. Each option represents the right to buy one share, so the award provides potential future ownership of 6,068 shares if the options are exercised after vesting.

What is the exercise price and expiration date of John Maraganore’s Kymera (KYMR) options?

The options have an exercise price of $99.87 per share and expire on June 23, 2036. This means he can choose to buy shares at $99.87 any time after vesting and before the stated expiration date.

When do John Maraganore’s Kymera Therapeutics (KYMR) stock options vest?

The options vest in full on the earlier of June 24, 2027 or Kymera’s next annual stockholder meeting date. Once vesting occurs, he may exercise the options at the fixed price, subject to any applicable company or regulatory restrictions.

Is John Maraganore’s Kymera (KYMR) option grant an open-market share purchase?

No, the filing shows a grant of stock options, not an open-market share purchase. The transaction is coded as a grant or award, meaning the company awarded options that may later be exercised to buy shares at a set price.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MARAGANORE JOHN

(Last) (First) (Middle)

C/O KYMERA THERAPEUTICS, INC.

500 NORTH BEACON STREET, 4TH FLOOR

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Kymera Therapeutics, Inc. [ KYMR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$99.87	06/24/2026		A		6,068		(1)	06/23/2036	Common Stock	6,068	$0	6,068	D

Explanation of Responses:

1. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 24, 2027 and (ii) the date of the next annual meeting of the Issuer's stockholders.

	/s/ Bruce Jacobs, as Attorney-in-Fact	06/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)